Human Papillomavirus (HPV) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Condition: Human Papilloma Virus Infection Interventions: Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli); Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae) Sponsors: Beijing Health Guard Biotechnology, Inc; Jiangsu Province Centers for Disease Control and Prevention; National Institutes for Food and Drug Control, China; Nanjing Sangruisi pharmtech Ltd.; Shanghai Canming pharmtech Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2023 Category: Research Source Type: clinical trials

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Conditions: Cervical Cancer; Throat Cancer; Oropharynx Cancer; Anal Cancer; Vulva Cancer; Vaginal Cancer; Penile Cancer; Metastatic Cancer; HPV-Related Malignancy; HPV-Related Carcinoma; HPV-Related Cervical Carcinoma; HPV-Related Squamous Cell Carcinoma; H PV-Related Adenocarcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma; HPV-Associated Vaginal Adenocarcinoma; HPV-Related Adenosquamous Carcinoma; HPV-Related Endocervical Adenocarcinoma; HPV-Related Anal Squamous Cell Carcinoma; HPV-Related Penile Squamous Ce ll Carcinoma; ...
Source: ClinicalTrials.gov - January 17, 2023 Category: Research Source Type: clinical trials